Krystal Biotech Stock
Price
Target price
€224.80
€224.80
4.820%
10.3
4.820%
€210.68
09.01.26 / Tradegate
WKN: A2JH2F / Symbol: KRYS / Name: Krystal Biotech / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Krystal Biotech Stock
Krystal Biotech dominated the market today, gaining €10.30 (4.820%).
With 23 Buy predictions and not a single Sell prediction Krystal Biotech is an absolute favorite of our community.
However, we have a potential of -6.58% for Krystal Biotech as the target price of 210 € is below the current price of 224.8 €.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Krystal Biotech stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Krystal Biotech in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Krystal Biotech vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Krystal Biotech | 4.820% | 6.793% | 11.342% | 47.943% | 3.690% | 225.797% | - |
| Ardelyx Inc. | 8.590% | 26.964% | 33.347% | 29.131% | 35.546% | 163.162% | 23.939% |
| Evolus Inc | 0.000% | -15.439% | -18.305% | -49.792% | -11.560% | -32.113% | 57.208% |
| Champions Oncology Inc | 2.750% | 0.901% | 8.738% | 17.647% | -3.448% | 41.414% | -37.778% |
Comments
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at TD Cowen from $202.00 to $306.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Show more
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.
Show more
Ratings data for KRYS provided by MarketBeat
